Table 1:
Clinicopathological features of patients who underwent surgery for stage II–III colon cancer stratified by MSI statusa
| Characteristics | MSS (n = 134) | MSI (n = 64) | p value |
|---|---|---|---|
| Median age, years (range) | 51.5 (27–85) | 62.0 (29–86) | 0.007 |
| Gender | 0.84 | ||
| Female | 67 (50.0) | 33 (51.6) | |
| Male | 67 (50.0) | 31 (48.4) | |
| Primary tumor location | < 0.05 | ||
| Right | 63 (47.0) | 58 (90.6) | |
| Left | 71 (53.0) | 6 (9.4) | |
| T stage | 0.55 | ||
| T1 | 3 (2.2) | 1 (1.6) | |
| T2 | 10 (7.5) | 2 (3.1) | |
| T3 | 100 (74.6) | 53 (82.8) | |
| T4 | 21 (15.7) | 8 (12.5) | |
| Node-positive primary | |||
| No | 62 (46.3) | 46 (71.9) | <0.05 |
| Yes | 72 (53.7) | 18 (28.1) | <0.05 |
| N1 | 54 (40.3) | 12 (18.8) | |
| N2 | 18 (13.4) | 6 (9.4) | |
| Median number of positive nodes (range) | 1.0 (0–10) | 0.0 (0–8) | < 0.05 |
| Median total number of nodes (range) | 23.5 (11–119) | 28.0 (6–117) | 0.18 |
| CRC stage | < 0.05 | ||
| II | 62 (46.3) | 46 (71.9) | |
| III | 72 (53.7) | 18 (28.1) | |
| Tumor differentiation | < 0.05 | ||
| Poor | 26 (19.4) | 29 (45.3) | |
| Moderate | 108 (80.6) | 35 (54.7) | |
| Well | 0 (0.0) | 0 (0.0) | |
| Mucinous adenocarcinoma | < 0.05 | ||
| Yes | 37 (27.6) | 32 (50.0) | |
| No | 97 (72.4) | 32 (50.0) | |
| Tumor budding | < 0.05 | ||
| Yes | 40 (29.9) | 7 (10.9) | |
| No | 29 (21.6) | 15 (23.4) | |
| Unknown | 65 (48.5) | 42 (65.6) | |
| Tumor infiltrating lymphocytes | < 0.05 | ||
| Yes | 16 (11.9) | 22 (34.4) | |
| No | 60 (44.8) | 11 (17.2) | |
| Unknown | 58 (43.3) | 31 (48.4) | |
| Perineural invasion | 0.098 | ||
| Yes | 45 (33.6) | 14 (21.9) | |
| No | 86 (64.2) | 50 (78.1) | |
| Unknown | 3 (2.2) | 0 (0.0) | |
| Vascular invasion | < 0.05 | ||
| Yes | 78 (58.2) | 24 (37.5) | |
| No | 56 (41.8) | 40 (62.5) | |
| Positive margin | 0.15 | ||
| Yes | 0 (0.0) | 1 (1.6) | |
| No | 134 (100.0) | 63 (98.4) | |
| KRAS mutant | < 0.05 | ||
| Yes | 6 (4.5) | 4 (6.3) | |
| No | 11 (8.2) | 13 (20.3) | |
| Unknown | 117 (87.3) | 47 (73.4) | |
| BRAF mutant | 0.17 | ||
| Yes | 5 (3.7) | 5 (7.8) | |
| No | 14 (10.4) | 11 (17.2) | |
| Unknown | 115 (85.8) | 48 (75.0) | |
| HNPCCb | - | ||
| Yes | - | 15 (23.4) | |
| Sporadic | - | 16 (25.0) | |
| Unknown | - | 33 (51.6) |
a
Values in the table are numbers of patients (percentages) unless otherwise indicated
b
Confirmed after V600E BRAF mutation and/or MLH1 hypermethylation promoter assays MSI, Microsatellite instability; MSS, Microsatellite stability; CRC, Colorectal cancer; HNPCC, Hereditary nonpolyposis colorectal cancer